PNC Financial Services Group’s SpyGlass Pharma SGP Stock Holding History

PNC Financial Services Group’s Portfolio SGP Stock Details SGP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.6K	Buy	+370	New	+$9.12K	﹤0.01%	4204

Other funds holding SGP

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

PNC Financial Services Group's SGP Position: Q3 2026 in Review

PNC Financial Services Group opened a new position in SpyGlass Pharma (SGP) in Q3 2026: 370 shares worth $9.6K. The stake represents ﹤0.01% of the portfolio and ranks #4204 among its holdings.

20 funds tracked by Wall St. Rank hold SGP as of Q3 2026.

PNC Financial Services Group held 370 shares of SpyGlass Pharma worth $9.6K as of Q3 2026.
SpyGlass Pharma was a new PNC Financial Services Group position in Q3 2026.
SpyGlass Pharma made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4204 holding.
20 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.